{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:47:49Z","timestamp":1792036069960,"version":"4.4.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Exploratory Research in Clinical and Social Pharmacy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.rcsop.2026.100830","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:49:39Z","timestamp":1786981779000},"page":"100830","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["In defence of the drug, two hearts, one profession: Reintegrating medicines expertise and patient-centred care in pharmacy's professional identity"],"prefix":"10.1016","volume":"23","author":[{"given":"Neal M.","family":"Davies","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.rcsop.2026.100830_bb0005","first-page":"533","article-title":"Opportunities and responsibilities in pharmaceutical care","volume":"47","author":"Hepler","year":"1990","journal-title":"Am J Hosp Pharm"},{"key":"10.1016\/j.rcsop.2026.100830_bb0010","first-page":"1720","article-title":"ASHP statement on pharmaceutical care","volume":"50","author":"American Society of Hospital Pharmacists","year":"1993","journal-title":"Am J Hosp Pharm"},{"key":"10.1016\/j.rcsop.2026.100830_bb0015","series-title":"Animals with multiple hearts: octopus, squid, cuttlefish, hagfish and earthworm circulatory anatomy","year":"2026"},{"issue":"4","key":"10.1016\/j.rcsop.2026.100830_bb0020","first-page":"557","article-title":"Cardiovascular function in the hagfish: regulation of blood pressure and accessory hearts","volume":"99A","author":"Forster","year":"1991","journal-title":"Comp Biochem Physiol"},{"key":"10.1016\/j.rcsop.2026.100830_bb0025","author":"Worshipful Society of Apothecaries of London"},{"key":"10.1016\/j.rcsop.2026.100830_bb0030","series-title":"The Edinburgh Pharmacopoeia","author":"Royal College of Physicians of Edinburgh","year":"1699"},{"key":"10.1016\/j.rcsop.2026.100830_bb0035","article-title":"659 CE. See: A brief history of pharmacopoeias: a global perspective","author":"Tang dynasty Xinxiu bencao (newly revised canon of materia medica)","year":"2014","journal-title":"Pharm Technol"},{"key":"10.1016\/j.rcsop.2026.100830_bb0040","unstructured":"Wermuth CG, Aldous D, Raboisson P, Rognan D, eds. The practice of medicinal chemistry. 4th ed. Amsterdam: Academic Press; 2015."},{"issue":"4","key":"10.1016\/j.rcsop.2026.100830_bb0045","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/01.CIR.94.4.817","article-title":"HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine","volume":"94","author":"Roy","year":"1996","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.rcsop.2026.100830_bb0050","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat Rev Mater"},{"key":"10.1016\/j.rcsop.2026.100830_bb0055","series-title":"USP general chapter <795> pharmaceutical compounding, nonsterile preparations","author":"United States Pharmacopeia","year":"2023"},{"key":"10.1016\/j.rcsop.2026.100830_bb0060","first-page":"83","article-title":"Dose calculation of medicines in neonates and children","volume":"45","author":"Allegaert","year":"2019","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.rcsop.2026.100830_bb0065","series-title":"Professional competencies for pharmacists and pharmacy technicians at entry to practice in Canada","author":"National Association of Pharmacy Regulatory Authorities (NAPRA)","year":"2024"},{"key":"10.1016\/j.rcsop.2026.100830_bb0070","series-title":"Model compounding competencies for pharmacists and pharmacy technicians in Canada","author":"National Association of Pharmacy Regulatory Authorities (NAPRA)","year":"2022"},{"issue":"3","key":"10.1016\/j.rcsop.2026.100830_bb0075","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","article-title":"A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharm Res"},{"key":"10.1016\/j.rcsop.2026.100830_bb0080","series-title":"Clinical pharmacokinetics and pharmacodynamics: concepts and Applications","author":"Rowland","year":"2010"},{"issue":"11","key":"10.1016\/j.rcsop.2026.100830_bb0085","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health-Syst Pharm"},{"key":"10.1016\/j.rcsop.2026.100830_bb0090","series-title":"Accreditation standards and key elements for the professional program in pharmacy leading to the PharmD degree (standards 2025)","author":"Accreditation Council for Pharmacy Education","year":"2024"},{"issue":"6","key":"10.1016\/j.rcsop.2026.100830_bb0095","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B*5701 screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.rcsop.2026.100830_bb0100","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/cpt.1651","article-title":"The clinical pharmacogenetics implementation consortium: 10 years later","volume":"107","author":"Relling","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.rcsop.2026.100830_bb0105","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/cpt.2526","article-title":"Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update","volume":"112","author":"Lee","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.rcsop.2026.100830_bb0110","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors (NETTER-1)","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.rcsop.2026.100830_bb0115","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer (VISION)","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.rcsop.2026.100830_bb0120","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/S1470-2045(24)00407-8","article-title":"Radiotherapy and theranostics: a lancet oncology commission","volume":"25","author":"Abdel-Wahab","year":"2024","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.rcsop.2026.100830_bb0125","doi-asserted-by":"crossref","first-page":"e250","DOI":"10.1016\/S1470-2045(24)00037-8","article-title":"Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: workforce challenges and training in the age of theranostics","volume":"25","author":"Scott","year":"2024","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.rcsop.2026.100830_bb0130","first-page":"153","article-title":"Pharmacognosy: a discipline at the crossroads with many opportunities","volume":"76","author":"Heinrich","year":"2012","journal-title":"Am J Pharm Educ"},{"issue":"3","key":"10.1016\/j.rcsop.2026.100830_bb0135","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1021\/acs.jnatprod.9b01285","article-title":"Natural products as sources of new drugs over the nearly four decades from 01\/1981 to 09\/2019","volume":"83","author":"Newman","year":"2020","journal-title":"J Nat Prod"},{"key":"10.1016\/j.rcsop.2026.100830_bb0140","author":"United States Food and Drug Administration"},{"key":"10.1016\/j.rcsop.2026.100830_bb0145","article-title":"Artificial intelligence in the field of pharmacy practice: a literature review","volume":"12","author":"Chalasani","year":"2023","journal-title":"Explor Res Clin Soc Pharm"},{"issue":"2","key":"10.1016\/j.rcsop.2026.100830_bb0150","doi-asserted-by":"crossref","DOI":"10.24926\/iip.v13i2.4839","article-title":"Artificial intelligence (AI) in pharmacy: an overview of innovations","volume":"13","author":"Raza","year":"2022","journal-title":"Innov Pharm"},{"key":"10.1016\/j.rcsop.2026.100830_bb0155","article-title":"ASHP statement on the use of artificial intelligence in pharmacy","author":"American Society of Health-System Pharmacists","year":"2024","journal-title":"Am J Health-Syst Pharm"},{"issue":"1","key":"10.1016\/j.rcsop.2026.100830_bb0160","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jama.1995.03530010043033","article-title":"Incidence of adverse drug events and potential adverse drug events. Implications for prevention","volume":"274","author":"Bates","year":"1995","journal-title":"JAMA"},{"issue":"9823","key":"10.1016\/j.rcsop.2026.100830_bb0165","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/S0140-6736(11)61817-5","article-title":"A pharmacist led information technology intervention for medication errors (PINCER): a multicentre, cluster randomised, controlled trial and cost-effectiveness analysis","volume":"379","author":"Avery","year":"2012","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.rcsop.2026.100830_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077169","article-title":"Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis","volume":"8","author":"Ye","year":"2013","journal-title":"PloS One"},{"issue":"10","key":"10.1016\/j.rcsop.2026.100830_bb0175","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1345\/aph.1D091","article-title":"Fatality from administration of labetalol and crushed extended release nifedipine","volume":"37","author":"Schier","year":"2003","journal-title":"Ann Pharmacother"},{"issue":"7","key":"10.1016\/j.rcsop.2026.100830_bb0180","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1503\/cmaj.050176","article-title":"Avoid the crush: hazards of medication administration in patients with dysphagia or a feeding tube","volume":"172","author":"Cornish","year":"2005","journal-title":"CMAJ"},{"issue":"9","key":"10.1016\/j.rcsop.2026.100830_bb0185","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.3390\/ph15091091","article-title":"The role of pharmaceutical compounding in promoting medication adherence","volume":"15","author":"Carvalho","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"10.1016\/j.rcsop.2026.100830_bb0190","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3390\/pharmaceutics18010126","article-title":"Extemporaneous formulations for pediatric patients: global necessities, challenges and opportunities","volume":"18","author":"Aulakh","year":"2026","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.rcsop.2026.100830_bb0195","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/1715163517745517","article-title":"Pharmacists as accessible primary health care providers: review of the evidence","volume":"151","author":"Tsuyuki","year":"2018","journal-title":"Can Pharm J (Ott)"},{"key":"10.1016\/j.rcsop.2026.100830_bb0200","unstructured":"Canadian Council for Accreditation of Pharmacy Programs. Educational outcomes for the first professional degree programs in pharmacy in canada. Toronto: CCAPP; current edition."},{"key":"10.1016\/j.rcsop.2026.100830_bb0205","series-title":"Person-centredness is at the heart of ACP\u2019s draft standards of practice","author":"Alberta College of Pharmacy","year":"2024"},{"key":"10.1016\/j.rcsop.2026.100830_bb0210","author":"Alberta College of Pharmacy"},{"key":"10.1016\/j.rcsop.2026.100830_bb0215","series-title":"Standards of practice for pharmacists and pharmacy technicians","author":"Alberta College of Pharmacy","year":"2025"},{"key":"10.1016\/j.rcsop.2026.100830_bb0220","unstructured":"Alberta Pharmacists'\u2019 Association (RxA). Advocacy. Edmonton: RxA. Available from: https:\/\/rxa.ca\/professional-practice\/advocacy\/ (accessed 18 July 2026)."},{"key":"10.1016\/j.rcsop.2026.100830_bb0225","series-title":"Statement of policy: people-centred pharmaceutical care","author":"International Pharmaceutical Federation (FIP)","year":"2022"},{"key":"10.1016\/j.rcsop.2026.100830_bb0230","series-title":"FIP development goals (DG14: medicines expertise; DG15: people-centred care)","author":"International Pharmaceutical Federation (FIP)","year":"2020"},{"key":"10.1016\/j.rcsop.2026.100830_bb0235","series-title":"FIP global competency framework: supporting the development of foundation and early career pharmacists, version 2","author":"International Pharmaceutical Federation (FIP)","year":"2020"},{"issue":"1","key":"10.1016\/j.rcsop.2026.100830_bb0240","article-title":"Development of the 2025 ACPE accreditation standards leading to the doctor of pharmacy degree","volume":"89","author":"Kiersma","year":"2025","journal-title":"Am J Pharm Educ"},{"key":"10.1016\/j.rcsop.2026.100830_bb0245","series-title":"About CPhA","author":"Canadian Pharmacists Association","year":"2025"},{"key":"10.1016\/j.rcsop.2026.100830_bb0250","series-title":"Blueprint for Pharmacy initiative. Optimal drug therapy outcomes for Canadians through patient centred care","year":"2026"},{"key":"10.1016\/j.rcsop.2026.100830_bb0255","doi-asserted-by":"crossref","DOI":"10.1177\/17151635241285920","article-title":"Canadian pharmacists association: transforming primary care in Canada summit 2024 white paper","author":"Liu","year":"2024","journal-title":"Can Pharm J (Ott)"},{"key":"10.1016\/j.rcsop.2026.100830_bb0260","series-title":"Model standards of practice for pharmacists and pharmacy technicians in Canada","author":"National Association of Pharmacy Regulatory Authorities (NAPRA)","year":"2022"},{"key":"10.1016\/j.rcsop.2026.100830_bb0265","unstructured":"University of Houston College of Pharmacy. PharmD curriculum: integrated organ-system module structure. Houston: UH. Available from: https:\/\/www.uh.edu\/pharmacy\/degrees-and-programs\/pharmd\/pharmd-curriculum\/ (accessed 18 July 2026)."},{"issue":"7","key":"10.1016\/j.rcsop.2026.100830_bb0270","first-page":"137","article-title":"Integrating a new medicinal chemistry and pharmacology course sequence into the PharmD curriculum: principles of drug action at the University of Michigan","volume":"78","author":"Stringer","year":"2014","journal-title":"Am J Pharm Educ"},{"key":"10.1016\/j.rcsop.2026.100830_bb0275","series-title":"DiPiro\u2019s pharmacotherapy: a pathophysiologic approach","year":"2026"},{"key":"10.1016\/j.rcsop.2026.100830_bb0280","series-title":"Innovations in pharmacy training and sustainable practice to advance patient care: proceedings of a workshop","author":"National Academies of Sciences, Engineering, and Medicine","year":"2024"},{"key":"10.1016\/j.rcsop.2026.100830_bb0285","author":"McGraw-Hill Medical, AccessPharmacy"},{"issue":"16","key":"10.1016\/j.rcsop.2026.100830_bb0290","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1093\/ajhp\/53.16.1911","article-title":"Searching for the soul of pharmacy","volume":"53","author":"Zellmer","year":"1996","journal-title":"Am J Health-Syst Pharm"},{"issue":"4","key":"10.1016\/j.rcsop.2026.100830_bb0295","first-page":"421","article-title":"Professionally determined need for pharmacy services in 2020","volume":"66","author":"Knapp","year":"2002","journal-title":"Am J Pharm Educ"},{"key":"10.1016\/j.rcsop.2026.100830_bb0300","unstructured":"University of Manitoba. Doctor of Pharmacy (PharmD) curriculum: pharmacokinetics-pharmacodynamics and clinical therapeutics course sequence. Winnipeg: University of Manitoba Academic Calendar. Available from: https:\/\/catalog.umanitoba.ca\/undergraduate-studies\/health-sciences\/pharmacy\/pharmacy-pharmd\/ (accessed 19 July 2026). 2026."},{"issue":"7","key":"10.1016\/j.rcsop.2026.100830_bb0305","doi-asserted-by":"crossref","first-page":"8829","DOI":"10.5688\/ajpe8829","article-title":"Overcoming past perceptions and a profession wide identity crisis to reflect pharmacy\u2019s future","volume":"86","author":"Wagner","year":"2022","journal-title":"Am J Pharm Educ"},{"issue":"1","key":"10.1016\/j.rcsop.2026.100830_bb0310","doi-asserted-by":"crossref","DOI":"10.1080\/20523211.2025.2511152","article-title":"Person centred care in pharmacy: time to walk the talk","volume":"18","author":"Al Diery","year":"2025","journal-title":"J Pharm Policy Pract"},{"issue":"11","key":"10.1016\/j.rcsop.2026.100830_bb0315","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1002\/jac5.1538","article-title":"The pharmacist\u2019s professional identity: preventing, identifying, and managing medication therapy problems as the medication specialist","volume":"4","author":"Nelson","year":"2021","journal-title":"JACCP J Am Coll Clin Pharm"},{"key":"10.1016\/j.rcsop.2026.100830_bb0320","series-title":"Patient centric approach in pharma: a departure from product or profit focused models","year":"2023"},{"key":"10.1016\/j.rcsop.2026.100830_bb0325","article-title":"Person centred over patient centred care: not just semantics","author":"Barnett","year":"2018","journal-title":"Pharm J"},{"key":"10.1016\/j.rcsop.2026.100830_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.sapharm.2026.07.008","article-title":"Educating pharmacists for an artificial intelligence augmented profession: a narrative review of curricular and accreditation imperatives","author":"Davies","year":"2026","journal-title":"Res Social Adm Pharm"}],"container-title":["Exploratory Research in Clinical and Social Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667276626001289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667276626001289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:17:24Z","timestamp":1792034244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667276626001289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":66,"alternative-id":["S2667276626001289"],"URL":"https:\/\/doi.org\/10.1016\/j.rcsop.2026.100830","relation":{},"ISSN":["2667-2766"],"issn-type":[{"value":"2667-2766","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In defence of the drug, two hearts, one profession: Reintegrating medicines expertise and patient-centred care in pharmacy's professional identity","name":"articletitle","label":"Article Title"},{"value":"Exploratory Research in Clinical and Social Pharmacy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rcsop.2026.100830","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100830"}}